HCW Biologics Inc.
(NASDAQ:HCWB) stock fell during Tuesday's session.
The company announced preliminary results from its Phase 1 trial for HCW9302, an IL-2-based treatment for alopecia areata.
All participants in the second-dose cohort showed clinical responses after a single dose of the treatment, which was well tolerated, with no significant adverse effects reported, including no cases of cytokine release syndrome or capillary leak syndrome.
The company is progressing through dose escalation in this clinical study, aiming to establish the recommended Phase 2 dose by the end of 2026.
